Grants8

Grant Information	Key Details	Eligibility & Funding
Strategic Integrated Projects - Climate Action 48210282TOPICSen Programme: LIFE	This grant, 'LIFE-2025-STRAT-CLIMA-SIP-two-stage', aims to support the full implementation of key climate-related plans and strategies, such as National Energy and Climate Plans, national or regional adaptation strategies, urban climate action plans, or industry-specific greenhouse gas mitigation roadmaps. It targets organizations and stakeholders responsible for these plans, seeking to catalyze a process that mobilizes complementary funding and leads to comprehensive implementation. This is a SECTOR-SPECIFIC grant, focusing exclusively on climate action and energy transition within the framework of pre-defined national, regional, urban, or sector-specific strategies. The geographic scope is not explicitly detailed in the provided materials but is expected to align with the territories covered by the national/regional plans being implemented.	Funding Up to None EUR Deadline March 5, 2026, midnight	Details
Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required) PAR-24-329 Programme: National Institutes of Health (NIH)	This grant aims to support formative research, intervention development, and pilot-testing of novel or adapted interventions for people who use substances. - The core objective is to improve HIV prevention, treatment, and program implementation, focusing on feasibility, acceptability, and safety of these interventions. - Target recipients are primarily research institutions, non-profits, for-profit organizations, and various governmental entities capable of conducting clinical trials. - SECTOR-SPECIFIC: This grant is specifically focused on public health, particularly HIV/AIDS and substance use disorders. - Geographic scope is global; domestic and overseas studies are considered, with eligibility for non-U.S. entities. - Key filtering criteria include the necessity of a clinical trial, focus on substance use in relation to HIV, and engagement of 'end users'. - This is a recurring grant opportunity with multiple application cycles through May 2027, reissuing a previous program announcement.	Funding Up to 450000.00 USD Deadline May 7, 2027, 5 p.m.	Details
Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed) PAR-25-060 Programme: Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program	This grant, part of the 'Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program', aims to foster the development and validation of animal models and human/animal tissue ex vivo systems. These models must accurately reflect the characteristics of specific neurological or neuromuscular disorders to significantly improve their relevance for future neurotherapeutic discovery. The grant is SECTOR-SPECIFIC, focusing exclusively on the healthcare and biomedical research sectors, particularly neuroscience and drug discovery. It targets a wide range of organizations involved in research, including academic institutions, non-profits, for-profits (including small businesses), and various government entities in the U.S. and internationally. The key filtering criteria are the grant's explicit focus on model development and validation for neurological/neuromuscular diseases, with clinical trials not allowed. It also requires a phased approach (R61/R33) with clear milestones. This is a recurring funding opportunity with multiple application cycles available until October 2027, reissuing a previous call.	Funding Up to 750000.00 USD Deadline Oct. 20, 2027, 10 p.m.	Details
NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed) PA-25-304 Programme: National Institutes of Health (NIH)	The NIH Exploratory/Developmental Research Project Grant (R21) aims to support high-risk, high-reward exploratory and developmental research projects in biomedical, behavioral, and clinical fields. This funding is designed for the early and conceptual stages of projects that introduce novel scientific ideas, techniques, or technologies with the potential for significant breakthroughs or major impact. It specifically targets research that is exploratory and novel, rather than long-term projects or those in well-established areas. This grant is SECTOR-SPECIFIC, focusing on biomedical, behavioral, and clinical research. It is open to a very broad range of organization types, including academic institutions, non-profits, for-profit entities (small and large businesses), and various levels of government and community organizations, both domestic (US) and international. The geographic scope is worldwide, as non-U.S. entities are eligible to apply.	Funding Up to 275000.00 USD Deadline Nov. 16, 2027, 5 p.m.	Details
Technopark Kielce Startup Booster Poland Technopark Kielce Startup Booster Poland Programme: Polska Agencja Rozwoju Przedsiębiorczości (PARP) Accelerator Programs	This grant aims to support innovative startups, micro, and small enterprises by accelerating their growth and facilitating expansion into new markets through tailored acceleration activities and equity-free grants. Target recipient type and size: Startups, micro-enterprises, and small enterprises. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-AGNOSTIC Geographic scope: Project implementation in Poland, with a territorial reach that includes Poland and international markets. Key filtering criteria: Applicant must be a micro or small enterprise. The proposed innovative solution must meet specific Technology Readiness Level (TRL) requirements (TRL 5 or TRL 9). Project must align with one of the defined acceleration paths. Grant frequency and program context: The grant is part of a recurring program, with application periods conducted in multiple rounds.	Funding Up to 400000.00 PLN Deadline Jan. 31, 2026, 3:30 p.m.	Details
Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) PAR-25-184 Programme: National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunities	To support early-stage clinical trials testing novel pharmacologic or neuromodulatory device-based interventions for mental disorders. The core objective is to objectively measure and validate the intervention's molecular/circuit-based mechanism of action in humans. Target recipient types: Open to diverse organization types including higher education, nonprofits, for-profits (small businesses and others), and governments. Organizational size: Open to organizations of various sizes, without explicit employee count limitations beyond the capacity to conduct clinical trials. SECTOR-SPECIFIC: Mental Health, Clinical Neuroscience, Pharmacology, Neuromodulation, Device Development, Public Health. Geographic scope: Global eligibility, including non-U.S. entities. Key filtering criteria: Must involve a clinical trial, focus on early-stage testing of novel pharmacologic or neuromodulatory device interventions for mental disorders, and include objective target engagement measurement with Go/No-Go milestones. Grant frequency: Recurring opportunity with multiple deadlines annually until October 2027; reissued from a previous PAR, indicating an ongoing program within NIMH's clinical trial pipeline.	Funding Up to None USD Deadline Oct. 15, 2027, 5 p.m.	Details
Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required) PAR-25-206 Programme: National Institutes of Health (NIH) Funding Opportunity	This grant, PAR-25-206, aims to fund pilot effectiveness trials for interventions and services designed for the post-acute management of mental health conditions. The goal is to evaluate the feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of these approaches. This includes assessing whether the interventions engage their intended mechanisms and generating preliminary data for larger-scale effectiveness trials. This funding opportunity is SECTOR-SPECIFIC, focusing primarily on the mental health and healthcare sectors. It targets a broad range of organizational types, including academic institutions, nonprofits, for-profit businesses, and various government entities, allowing for varied organizational sizes. The grant has a global geographic scope, as non-U.S. entities are eligible to apply. It is a recurring grant with multiple application deadlines until its expiration date.	Funding Up to 750000.00 USD Deadline Nov. 5, 2027, 5 p.m.	Details
NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) PAR-23-076 Programme: NIDA Research Center of Excellence Grant Program (P50 Specialized Center)	This grant aims to establish and support NIDA Research Centers of Excellence (P50 Specialized Centers) that conduct innovative, multidisciplinary research in substance use and addiction, including its intersection with HIV. These Centers are expected to transform scientific fields, foster collaborations, facilitate data and tool sharing, and serve as national resources for education and outreach. Target Recipient Type: Research institutions capable of hosting complex, multidisciplinary research centers. Target Recipient Size: Not explicitly defined by employee count, but implies a significant capacity for research and administration. Designation: SECTOR-SPECIFIC (focused on substance use and addiction research). Geographic Scope: Organizations within the United States and its territories/possessions are eligible to apply. Foreign components (e.g., international research collaborators) are allowed within a US-based application. Key Filtering Criteria: Must be a research-focused organization with a strong track record in substance use/addiction research or related fields, capable of establishing a multidisciplinary center with integrated projects. Grant Frequency and Program Context: This is a recurring funding opportunity (reissue of PAR-22-133) with multiple application due dates extending into 2025. It's part of the National Institutes of Health (NIH) P50 Specialized Center grant mechanism, designed for complex, multi-component research programs.	Funding Up to 10000000.00 USD Deadline Sept. 25, 2025, 5 p.m.	Details
Laboratorium Innowatora – Strefa Kreatywnych Pomysłów 2.27 FENG Laboratorium Innowatora Programme: Fundusze Europejskie dla Nowoczesnej Gospodarki	This grant aims to provide comprehensive mentoring support to individual innovators interested in developing innovative products and establishing/growing a startup business. It helps selected idea holders work on their business model development. - Target recipient type: Individual innovators (private individuals or teams of private individuals). - Target size: Not applicable, as it targets individuals, not established organizations. - SECTOR-AGNOSTIC - Geographic scope: Poland. - Key filtering criteria: Applicant must be an individual with an innovative business idea and possess rights to that idea. - Grant frequency: Recurring in rounds. - Program context: Part of the 'European Funds for a Modern Economy' program (Fundusze Europejskie dla Nowoczesnej Gospodarki).	Funding Up to 50000.00 PLN Deadline April 30, 2026, 10:59 p.m.	Details
Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required) PA-25-163 Programme: National Institutes of Health (NIH) Funding Opportunity, National Institute on Alcohol Abuse and Alcoholism (NIAAA)	This grant, PA-25-163, from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH, aims to advance research specifically focused on Alcohol Use Disorder (AUD) treatment, pharmacotherapy, and recovery. It is exclusively for projects that involve clinical trials in humans. It is a SECTOR-SPECIFIC grant, targeting the healthcare and research sectors, with a primary focus on individuals affected by AUD. The grant broadly encourages studies on medications, behavioral therapies, recovery processes, translational research, and innovative technologies for AUD treatment. The geographic scope is global, as non-U.S. entities are eligible to apply. Key filtering criteria include the mandatory clinical trial component, the strict focus on AUD (excluding other substance use disorders or HIV-AIDS related studies), and the requirement for human-only studies (no preclinical animal studies). This is a recurring grant opportunity with multiple application deadlines until its expiration in September 2026, reissuing a previous program.	Funding Up to 500000.00 USD Deadline June 5, 2026, 9 p.m.	Details
Diversifying aquaculture production with emphasis on low-trophic species HORIZON-CL6-2025-02-FARM2FORK-10 Programme: Horizon Europe	Core objective: To diversify EU aquaculture production with an emphasis on low-trophic species and sustainable production methods, aiming to enhance the competitiveness and profitability of the sector, reduce its environmental impact, and increase consumer access to varied, EU-produced edible aquatic species. Explicit identification of target recipient type and size: The grant targets a wide range of organizations, including businesses (with particular promotion for SMEs), research organizations, public bodies, and civil society actors, involved in aquaculture and food systems. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC Geographic scope and any location requirements: Open to legal entities from EU Member States and Horizon Europe Associated Countries. International cooperation is encouraged, and certain non-associated low-to-middle income countries are automatically eligible for funding. Participation from other non-associated countries is possible, but usually without direct funding unless explicitly stated. Key filtering criteria for initial grant screening: Projects must focus on aquaculture diversification, specifically involving low-trophic species or sustainable alternative feed sources, and aim for environmental, economic, and social impacts in the EU aquaculture sector. A strong innovation component is essential. Grant frequency and program context: This is a single-stage call within the Horizon Europe Work Programme 2025 (Cluster 6), indicating a recurring program with specific annual calls.	Funding Up to 6000000.00 EUR Deadline Sept. 16, 2025, midnight	Details
AccelStart: Support for innovative business ideas for individuals who have never conducted business activity, primarily in Insurtech, Fintech, and Telco. FENG.02.27-IP.02-0028/23-00 Programme: European Funds for a Modern Economy Program 2021-2027 (FENG)	The AccelStart grant aims to support individuals or teams with innovative IT and technology business ideas, particularly in Insurtech, Fintech, and Telco sectors. The core objective is to help them develop their concepts into a Minimum Viable Product (MVP) before formally establishing a business. This is a SECTOR-SPECIFIC grant for early-stage innovators in Poland, running with continuous intake until October 2026, as part of the broader European Funds for a Modern Economy Program 2021-2027.	Funding Up to None PLN Deadline Oct. 30, 2026, 10:59 p.m.	Details
National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) RFA-CA-24-026 Programme: NIH Research Education Program (R25)	Core objective: To encourage individuals without substantial biomedical research experience to pursue further studies or careers in research, specifically in cancer, via early intervention strategies. Explicit identification of target recipient type and size: Open to a wide range of U.S. organizations including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities and other organizations (e.g., independent school districts). No specific organizational size based on employee count is stated. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC Geographic scope and any location requirements: Limited to U.S. organizations only; non-U.S. entities or components are not eligible. Key filtering criteria for initial grant screening: Must be a U.S.-based institution capable of developing and maintaining an institutional program focused on engaging grades 6-12 and/or undergraduate students in cutting-edge cancer research experiences. The program must include Research Experiences, Curriculum or Methods Development, and Outreach, and cannot involve clinical trials. Grant frequency and program context: This is a reissue of a previous RFA, implying a recurring opportunity. It is part of the NIH Research Education Program (R25), supporting NCI's mission to build the cancer research pipeline from middle school to independent researcher status.	Funding Up to 2000000.00 USD Deadline Sept. 28, 2026, 5 p.m.	Details
NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed) PAR-24-209 Programme: NIH Research Career Development program (K22 Career Transition Award)	This grant, the 'NHLBI Career Transition Award (K22)', is designed for highly qualified postdoctoral fellows and doctoral-level researchers currently training within the National Heart, Lung, and Blood Institute's (NHLBI) Intramural Research Division. Its core objective is to help these individuals smoothly transition into independent research positions at extramural institutions (like universities or research organizations). It provides support for both a mentored research phase within NHLBI and a subsequent independent research phase at an external organization. This is a SECTOR-SPECIFIC grant, focused on biomedical, behavioral, and clinical research relevant to NHLBI's mission (heart, lung, blood, and sleep-related health). The geographic scope is U.S. organizations and individuals. A key filtering criterion is that the proposed research must not involve leading an independent clinical trial. This is a recurring grant opportunity with multiple application deadlines each year, and it's a reissue of a previous program (PAR-22-034), indicating an ongoing commitment to this career development pathway.	Funding Up to 747000.00 USD Deadline June 12, 2027, 5 p.m.	Details
NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed) PAR-23-175 Programme: P30 Center Core Grants	Single, clear statement of grant's core objective: To enhance vision research by providing shared core resources and services to a group of independently funded NEI R01 investigators, fostering collaboration and increasing research productivity. Explicit identification of target recipient type and size: Institutions (Higher Education, Nonprofits, For-Profit, Government, Other) with 8 or more active NEI-supported R01 grants. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC Geographic scope and any location requirements: United States. Foreign institutions and components are not eligible. Key filtering criteria for initial grant screening: Must be a US-based institution with at least 8 active NEI R01 grants. Must not involve clinical trials or direct human subjects research. Grant frequency and program context: Recurring opportunity (reissue of PAR-20-051) with annual application windows. A P30 Center Core Grant, designed to support shared infrastructure for existing research.	Funding Up to 2500000.00 USD Deadline Sept. 30, 2025, 5 p.m.	Details
BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed) RFA-NS-25-018 Programme: BRAIN Initiative	GRANT PURPOSE AND TARGET: - To develop new technologies and novel approaches for recording and modulation of neural cells and circuits. - Focus is on addressing major challenges and enabling transformative understanding of dynamic signaling in the central nervous system. - Target recipients: Researchers and organizations involved in neuroscience and technology development. - SECTOR-SPECIFIC - Geographic scope: Global, as non-U.S. entities are eligible. - Key filtering criteria: Focus on technology development for CNS recording/modulation, not biological discovery; clinical trials are not allowed; early-stage, high-risk projects are encouraged. - Grant frequency: Reissue of a previous funding opportunity, indicating recurring nature within the BRAIN Initiative program.	Funding Up to None USD Deadline Jan. 21, 2026, 5 p.m.	Details
Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction HORIZON-JU-IHI-2025-11-01-two-stage Programme: Horizon Europe	This grant, 'Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction', aims to revolutionize how brain disorders are diagnosed and treated. Its core objective is to develop a sustainable, large-scale data platform to identify new biological markers for brain dysfunctions, specifically focusing on Reward/Motivation & Impulsivity (RM&I) symptoms that cut across conditions like Alzheimer's, major depressive disorder, and obesity. The goal is to move towards more personalized healthcare by understanding the shared biological underpinnings of these symptoms. This is a SECTOR-SPECIFIC grant primarily targeting the Healthcare and Technology sectors, specifically focusing on neuroscience, digital health, and public health. It seeks significant research organizations, universities, and industry partners capable of undertaking large-scale research and innovation projects. Legal entities from EU Member States, the UK, and Canada are eligible to receive funding. The ultimate impact is expected to benefit patients and healthcare systems across Europe and beyond. Key filtering criteria for potential applicants include a focus on brain dysfunction research (specifically RM&I symptoms), the ability to integrate and leverage existing data platforms (not build new ones from scratch), a track record in significant research, and a willingness to form a consortium with a mandatory 45% industry financial contribution for the second stage of the application. This grant is part of the Innovative Health Initiative Joint Undertaking's (IHI JU) annual call (Call 11) under the broader Horizon Europe program, indicating a recurring funding opportunity with a focus on public-private partnerships.	Funding Up to 20202000.00 EUR Deadline April 29, 2026, midnight	Details
Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) PAR-25-338 Programme: National Institutes of Health (NIH) Grants	This grant aims to stimulate the translation of scientific discoveries and engineering developments into practical methods and tools for understanding, assessing, detecting, preventing, diagnosing, treating, and managing diseases. It fosters collaboration by requiring academic-industrial partnerships. Single, clear statement of grant's core objective: To translate biomedical scientific and engineering discoveries into new methods or tools for disease diagnosis and treatment through academic-industrial partnerships, explicitly excluding clinical trials. Explicit identification of target recipient type and size: Research teams composed of at least one academic organization and one industrial organization, regardless of specific organizational size, but needing sufficient expertise and resources. MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Healthcare, Biotechnology, Medical Research, Diagnostics, Medical Technology). Geographic scope and any location requirements: Domestic (U.S.) and foreign organizations are eligible. Key filtering criteria for initial grant screening: Must propose an academic-industrial partnership. Must focus on translation of technology/methods; clinical trials are not allowed. Must not be for commercial production or basic research lacking a translational aim. Grant frequency and program context: Recurring funding opportunity, reissued from PAR-21-166, with multiple recurring submission deadlines up to October 2027.	Funding Up to 499000.00 USD Deadline Oct. 5, 2027, 5 p.m.	Details
SSbD bio-based polymers/copolymers unlocking new market applications HORIZON-JU-CBE-2025-IA-05 Programme: Circular Bio-based Europe Joint Undertaking	The core objective of this grant is to drive the development and market uptake of new Safe and Sustainable by Design (SSbD) bio-based polymers and copolymers. It aims to unlock novel market applications and improve the sustainability, safety, and circularity of bio-based materials compared to current benchmarks. The grant supports the demonstration and validation of these innovative solutions, fostering a broader acceptance of bio-based products. - Explicit identification of target recipient type and size: The grant targets a broad range of legal entities, including companies (SMEs and large enterprises), research organizations, and universities, capable of high-TRL research, development, and industrial demonstration. - SECTOR-SPECIFIC: This grant is highly sector-specific, focusing on bio-based chemistry, materials engineering, and the manufacturing of advanced bio-polymers and bio-plastics. It is also aligned with circular bioeconomy principles. - Geographic scope and any location requirements: The geographical scope includes entities established in EU Member States and countries associated with Horizon Europe. - Key filtering criteria for initial grant screening: Focus on bio-based polymers/copolymers, high technology readiness levels (TRL 5-7), integration of Safe and Sustainable by Design (SSbD) principles, and clear market application potential. - Grant frequency and program context: This is part of the Circular Bio-based Europe Joint Undertaking (CBE JU) annual work programme, suggesting a recurring nature within the broader Horizon Europe framework.	Funding Up to 7000000.00 EUR Deadline Sept. 18, 2025, midnight	Details
Nutrients produced by microorganisms utilising primarily CO2 from the air, with the support of biotechnology 48214342TOPICSen Programme: Horizon Europe	To develop and scale innovative processes for producing nutrients from atmospheric CO2 using genetically engineered microorganisms, fostering safer food systems and new business models in biotechnology. - Target recipient type and size: Industry, food-producing companies, research organizations, public bodies, NGOs. SMEs and start-ups are particularly promoted. - This grant is SECTOR-SPECIFIC, focusing on food systems, biotechnology, bioeconomy, and agriculture. - Geographic scope: EU Member States and Associated Countries. International cooperation (e.g., with the US, Africa) is encouraged. - Key filtering criteria: Focus on precision fermentation, CO2 utilization by microorganisms, food applications, and commitment to the multi-actor approach. - Grant frequency and context: Part of the Horizon Europe Cluster 6 Work Programme 2025, a recurring framework program with specific calls. This is a one-time call for this specific topic ID within the 2025 program.	Funding Up to 6000000.00 EUR Deadline Sept. 16, 2025, midnight	Details

Strategic Integrated Projects - Climate Action

48210282TOPICSen

Programme: LIFE

This grant, 'LIFE-2025-STRAT-CLIMA-SIP-two-stage', aims to support the full implementation of key climate-related plans and strategies, such as National Energy and Climate Plans, national or regional adaptation strategies, urban climate action plans, or industry-specific greenhouse gas mitigation roadmaps. It targets organizations and stakeholders responsible for these plans, seeking to catalyze a process that mobilizes complementary funding and leads to comprehensive implementation. This is a SECTOR-SPECIFIC grant, focusing exclusively on climate action and energy transition within the framework of pre-defined national, regional, urban, or sector-specific strategies. The geographic scope is not explicitly detailed in the provided materials but is expected to align with the territories covered by the national/regional plans being implemented.

Funding

Up to None EUR

Deadline

March 5, 2026, midnight

Details

Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)

PAR-24-329

Programme: National Institutes of Health (NIH)

This grant aims to support formative research, intervention development, and pilot-testing of novel or adapted interventions for people who use substances. - The core objective is to improve HIV prevention, treatment, and program implementation, focusing on feasibility, acceptability, and safety of these interventions. - Target recipients are primarily research institutions, non-profits, for-profit organizations, and various governmental entities capable of conducting clinical trials. - SECTOR-SPECIFIC: This grant is specifically focused on public health, particularly HIV/AIDS and substance use disorders. - Geographic scope is global; domestic and overseas studies are considered, with eligibility for non-U.S. entities. - Key filtering criteria include the necessity of a clinical trial, focus on substance use in relation to HIV, and engagement of 'end users'. - This is a recurring grant opportunity with multiple application cycles through May 2027, reissuing a previous program announcement.

Funding

Up to 450000.00 USD

Deadline

May 7, 2027, 5 p.m.

Details

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

PAR-25-060

Programme: Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program

This grant, part of the 'Innovation Grants to Nurture Initial Translational Efforts (IGNITE) Program', aims to foster the development and validation of animal models and human/animal tissue ex vivo systems. These models must accurately reflect the characteristics of specific neurological or neuromuscular disorders to significantly improve their relevance for future neurotherapeutic discovery. The grant is SECTOR-SPECIFIC, focusing exclusively on the healthcare and biomedical research sectors, particularly neuroscience and drug discovery. It targets a wide range of organizations involved in research, including academic institutions, non-profits, for-profits (including small businesses), and various government entities in the U.S. and internationally. The key filtering criteria are the grant's explicit focus on model development and validation for neurological/neuromuscular diseases, with clinical trials not allowed. It also requires a phased approach (R61/R33) with clear milestones. This is a recurring funding opportunity with multiple application cycles available until October 2027, reissuing a previous call.

Funding

Up to 750000.00 USD

Deadline

Oct. 20, 2027, 10 p.m.

Details

NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)

PA-25-304

Programme: National Institutes of Health (NIH)

The NIH Exploratory/Developmental Research Project Grant (R21) aims to support high-risk, high-reward exploratory and developmental research projects in biomedical, behavioral, and clinical fields. This funding is designed for the early and conceptual stages of projects that introduce novel scientific ideas, techniques, or technologies with the potential for significant breakthroughs or major impact. It specifically targets research that is exploratory and novel, rather than long-term projects or those in well-established areas. This grant is SECTOR-SPECIFIC, focusing on biomedical, behavioral, and clinical research. It is open to a very broad range of organization types, including academic institutions, non-profits, for-profit entities (small and large businesses), and various levels of government and community organizations, both domestic (US) and international. The geographic scope is worldwide, as non-U.S. entities are eligible to apply.

Funding

Up to 275000.00 USD

Deadline

Nov. 16, 2027, 5 p.m.

Details

Technopark Kielce Startup Booster Poland

Programme: Polska Agencja Rozwoju Przedsiębiorczości (PARP) Accelerator Programs

This grant aims to support innovative startups, micro, and small enterprises by accelerating their growth and facilitating expansion into new markets through tailored acceleration activities and equity-free grants.
Target recipient type and size: Startups, micro-enterprises, and small enterprises.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-AGNOSTIC
Geographic scope: Project implementation in Poland, with a territorial reach that includes Poland and international markets.
Key filtering criteria: Applicant must be a micro or small enterprise. The proposed innovative solution must meet specific Technology Readiness Level (TRL) requirements (TRL 5 or TRL 9). Project must align with one of the defined acceleration paths.
Grant frequency and program context: The grant is part of a recurring program, with application periods conducted in multiple rounds.

Funding

Up to 400000.00 PLN

Deadline

Jan. 31, 2026, 3:30 p.m.

Details

Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)

PAR-25-184

Programme: National Institute of Mental Health (NIMH) Clinical Trial Funding Opportunities

To support early-stage clinical trials testing novel pharmacologic or neuromodulatory device-based interventions for mental disorders.
The core objective is to objectively measure and validate the intervention's molecular/circuit-based mechanism of action in humans.
Target recipient types: Open to diverse organization types including higher education, nonprofits, for-profits (small businesses and others), and governments.
Organizational size: Open to organizations of various sizes, without explicit employee count limitations beyond the capacity to conduct clinical trials.
SECTOR-SPECIFIC: Mental Health, Clinical Neuroscience, Pharmacology, Neuromodulation, Device Development, Public Health.
Geographic scope: Global eligibility, including non-U.S. entities.
Key filtering criteria: Must involve a clinical trial, focus on early-stage testing of novel pharmacologic or neuromodulatory device interventions for mental disorders, and include objective target engagement measurement with Go/No-Go milestones.
Grant frequency: Recurring opportunity with multiple deadlines annually until October 2027; reissued from a previous PAR, indicating an ongoing program within NIMH's clinical trial pipeline.

Funding

Up to None USD

Deadline

Oct. 15, 2027, 5 p.m.

Details

Pilot Effectiveness Trials for Post-Acute Interventions and Services to Optimize Longer-term Outcomes (R01 Clinical Trial Required)

PAR-25-206

Programme: National Institutes of Health (NIH) Funding Opportunity

This grant, PAR-25-206, aims to fund pilot effectiveness trials for interventions and services designed for the post-acute management of mental health conditions. The goal is to evaluate the feasibility, tolerability, acceptability, safety, and preliminary indications of effectiveness of these approaches. This includes assessing whether the interventions engage their intended mechanisms and generating preliminary data for larger-scale effectiveness trials. This funding opportunity is SECTOR-SPECIFIC, focusing primarily on the mental health and healthcare sectors. It targets a broad range of organizational types, including academic institutions, nonprofits, for-profit businesses, and various government entities, allowing for varied organizational sizes. The grant has a global geographic scope, as non-U.S. entities are eligible to apply. It is a recurring grant with multiple application deadlines until its expiration date.

Funding

Up to 750000.00 USD

Deadline

Nov. 5, 2027, 5 p.m.

Details

NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)

PAR-23-076

Programme: NIDA Research Center of Excellence Grant Program (P50 Specialized Center)

This grant aims to establish and support NIDA Research Centers of Excellence (P50 Specialized Centers) that conduct innovative, multidisciplinary research in substance use and addiction, including its intersection with HIV. These Centers are expected to transform scientific fields, foster collaborations, facilitate data and tool sharing, and serve as national resources for education and outreach.

Target Recipient Type: Research institutions capable of hosting complex, multidisciplinary research centers.
Target Recipient Size: Not explicitly defined by employee count, but implies a significant capacity for research and administration.
Designation: SECTOR-SPECIFIC (focused on substance use and addiction research).
Geographic Scope: Organizations within the United States and its territories/possessions are eligible to apply. Foreign components (e.g., international research collaborators) are allowed within a US-based application.
Key Filtering Criteria: Must be a research-focused organization with a strong track record in substance use/addiction research or related fields, capable of establishing a multidisciplinary center with integrated projects.
Grant Frequency and Program Context: This is a recurring funding opportunity (reissue of PAR-22-133) with multiple application due dates extending into 2025. It's part of the National Institutes of Health (NIH) P50 Specialized Center grant mechanism, designed for complex, multi-component research programs.

Funding

Up to 10000000.00 USD

Deadline

Sept. 25, 2025, 5 p.m.

Details

Laboratorium Innowatora – Strefa Kreatywnych Pomysłów

2.27 FENG Laboratorium Innowatora

Programme: Fundusze Europejskie dla Nowoczesnej Gospodarki

This grant aims to provide comprehensive mentoring support to individual innovators interested in developing innovative products and establishing/growing a startup business. It helps selected idea holders work on their business model development. - Target recipient type: Individual innovators (private individuals or teams of private individuals). - Target size: Not applicable, as it targets individuals, not established organizations. - SECTOR-AGNOSTIC - Geographic scope: Poland. - Key filtering criteria: Applicant must be an individual with an innovative business idea and possess rights to that idea. - Grant frequency: Recurring in rounds. - Program context: Part of the 'European Funds for a Modern Economy' program (Fundusze Europejskie dla Nowoczesnej Gospodarki).

Funding

Up to 50000.00 PLN

Deadline

April 30, 2026, 10:59 p.m.

Details

Alcohol Treatment, Pharmacotherapy, and Recovery Research (R01 Clinical Trial Required)

PA-25-163

Programme: National Institutes of Health (NIH) Funding Opportunity, National Institute on Alcohol Abuse and Alcoholism (NIAAA)

This grant, PA-25-163, from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) of the NIH, aims to advance research specifically focused on Alcohol Use Disorder (AUD) treatment, pharmacotherapy, and recovery. It is exclusively for projects that involve clinical trials in humans. It is a SECTOR-SPECIFIC grant, targeting the healthcare and research sectors, with a primary focus on individuals affected by AUD. The grant broadly encourages studies on medications, behavioral therapies, recovery processes, translational research, and innovative technologies for AUD treatment. The geographic scope is global, as non-U.S. entities are eligible to apply. Key filtering criteria include the mandatory clinical trial component, the strict focus on AUD (excluding other substance use disorders or HIV-AIDS related studies), and the requirement for human-only studies (no preclinical animal studies). This is a recurring grant opportunity with multiple application deadlines until its expiration in September 2026, reissuing a previous program.

Funding

Up to 500000.00 USD

Deadline

June 5, 2026, 9 p.m.

Details

Diversifying aquaculture production with emphasis on low-trophic species

HORIZON-CL6-2025-02-FARM2FORK-10

Programme: Horizon Europe

Core objective: To diversify EU aquaculture production with an emphasis on low-trophic species and sustainable production methods, aiming to enhance the competitiveness and profitability of the sector, reduce its environmental impact, and increase consumer access to varied, EU-produced edible aquatic species.
Explicit identification of target recipient type and size: The grant targets a wide range of organizations, including businesses (with particular promotion for SMEs), research organizations, public bodies, and civil society actors, involved in aquaculture and food systems.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC
Geographic scope and any location requirements: Open to legal entities from EU Member States and Horizon Europe Associated Countries. International cooperation is encouraged, and certain non-associated low-to-middle income countries are automatically eligible for funding. Participation from other non-associated countries is possible, but usually without direct funding unless explicitly stated.
Key filtering criteria for initial grant screening: Projects must focus on aquaculture diversification, specifically involving low-trophic species or sustainable alternative feed sources, and aim for environmental, economic, and social impacts in the EU aquaculture sector. A strong innovation component is essential.
Grant frequency and program context: This is a single-stage call within the Horizon Europe Work Programme 2025 (Cluster 6), indicating a recurring program with specific annual calls.

Funding

Up to 6000000.00 EUR

Deadline

Sept. 16, 2025, midnight

Details

AccelStart: Support for innovative business ideas for individuals who have never conducted business activity, primarily in Insurtech, Fintech, and Telco.

FENG.02.27-IP.02-0028/23-00

Programme: European Funds for a Modern Economy Program 2021-2027 (FENG)

The AccelStart grant aims to support individuals or teams with innovative IT and technology business ideas, particularly in Insurtech, Fintech, and Telco sectors. The core objective is to help them develop their concepts into a Minimum Viable Product (MVP) before formally establishing a business. This is a SECTOR-SPECIFIC grant for early-stage innovators in Poland, running with continuous intake until October 2026, as part of the broader European Funds for a Modern Economy Program 2021-2027.

Funding

Up to None PLN

Deadline

Oct. 30, 2026, 10:59 p.m.

Details

National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed)

RFA-CA-24-026

Programme: NIH Research Education Program (R25)

Core objective: To encourage individuals without substantial biomedical research experience to pursue further studies or careers in research, specifically in cancer, via early intervention strategies.
Explicit identification of target recipient type and size: Open to a wide range of U.S. organizations including higher education institutions, non-profits, for-profit organizations (including small businesses), and various government entities and other organizations (e.g., independent school districts). No specific organizational size based on employee count is stated.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC
Geographic scope and any location requirements: Limited to U.S. organizations only; non-U.S. entities or components are not eligible.
Key filtering criteria for initial grant screening: Must be a U.S.-based institution capable of developing and maintaining an institutional program focused on engaging grades 6-12 and/or undergraduate students in cutting-edge cancer research experiences. The program must include Research Experiences, Curriculum or Methods Development, and Outreach, and cannot involve clinical trials.
Grant frequency and program context: This is a reissue of a previous RFA, implying a recurring opportunity. It is part of the NIH Research Education Program (R25), supporting NCI's mission to build the cancer research pipeline from middle school to independent researcher status.

Funding

Up to 2000000.00 USD

Deadline

Sept. 28, 2026, 5 p.m.

Details

NHLBI Career Transition Award for Intramural Postdoctoral Fellows and Research Trainees (K22 Independent Clinical Trial Not Allowed)

PAR-24-209

Programme: NIH Research Career Development program (K22 Career Transition Award)

This grant, the 'NHLBI Career Transition Award (K22)', is designed for highly qualified postdoctoral fellows and doctoral-level researchers currently training within the National Heart, Lung, and Blood Institute's (NHLBI) Intramural Research Division. Its core objective is to help these individuals smoothly transition into independent research positions at extramural institutions (like universities or research organizations). It provides support for both a mentored research phase within NHLBI and a subsequent independent research phase at an external organization. This is a SECTOR-SPECIFIC grant, focused on biomedical, behavioral, and clinical research relevant to NHLBI's mission (heart, lung, blood, and sleep-related health). The geographic scope is U.S. organizations and individuals. A key filtering criterion is that the proposed research must not involve leading an independent clinical trial. This is a recurring grant opportunity with multiple application deadlines each year, and it's a reissue of a previous program (PAR-22-034), indicating an ongoing commitment to this career development pathway.

Funding

Up to 747000.00 USD

Deadline

June 12, 2027, 5 p.m.

Details

NEI Center Core Grant for Vision Research (P30 Clinical Trial Not Allowed)

PAR-23-175

Programme: P30 Center Core Grants

Single, clear statement of grant's core objective: To enhance vision research by providing shared core resources and services to a group of independently funded NEI R01 investigators, fostering collaboration and increasing research productivity.
Explicit identification of target recipient type and size: Institutions (Higher Education, Nonprofits, For-Profit, Government, Other) with 8 or more active NEI-supported R01 grants.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC
Geographic scope and any location requirements: United States. Foreign institutions and components are not eligible.
Key filtering criteria for initial grant screening: Must be a US-based institution with at least 8 active NEI R01 grants. Must not involve clinical trials or direct human subjects research.
Grant frequency and program context: Recurring opportunity (reissue of PAR-20-051) with annual application windows. A P30 Center Core Grant, designed to support shared infrastructure for existing research.

Funding

Up to 2500000.00 USD

Deadline

Sept. 30, 2025, 5 p.m.

Details

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)

RFA-NS-25-018

Programme: BRAIN Initiative

GRANT PURPOSE AND TARGET: - To develop new technologies and novel approaches for recording and modulation of neural cells and circuits. - Focus is on addressing major challenges and enabling transformative understanding of dynamic signaling in the central nervous system. - Target recipients: Researchers and organizations involved in neuroscience and technology development. - SECTOR-SPECIFIC - Geographic scope: Global, as non-U.S. entities are eligible. - Key filtering criteria: Focus on technology development for CNS recording/modulation, not biological discovery; clinical trials are not allowed; early-stage, high-risk projects are encouraged. - Grant frequency: Reissue of a previous funding opportunity, indicating recurring nature within the BRAIN Initiative program.

Funding

Up to None USD

Deadline

Jan. 21, 2026, 5 p.m.

Details

Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction

HORIZON-JU-IHI-2025-11-01-two-stage

Programme: Horizon Europe

This grant, 'Towards precision medicine: platform for transdiagnostic stratification of brain dysfunction', aims to revolutionize how brain disorders are diagnosed and treated. Its core objective is to develop a sustainable, large-scale data platform to identify new biological markers for brain dysfunctions, specifically focusing on Reward/Motivation & Impulsivity (RM&I) symptoms that cut across conditions like Alzheimer's, major depressive disorder, and obesity. The goal is to move towards more personalized healthcare by understanding the shared biological underpinnings of these symptoms. This is a SECTOR-SPECIFIC grant primarily targeting the Healthcare and Technology sectors, specifically focusing on neuroscience, digital health, and public health. It seeks significant research organizations, universities, and industry partners capable of undertaking large-scale research and innovation projects. Legal entities from EU Member States, the UK, and Canada are eligible to receive funding. The ultimate impact is expected to benefit patients and healthcare systems across Europe and beyond. Key filtering criteria for potential applicants include a focus on brain dysfunction research (specifically RM&I symptoms), the ability to integrate and leverage existing data platforms (not build new ones from scratch), a track record in significant research, and a willingness to form a consortium with a mandatory 45% industry financial contribution for the second stage of the application. This grant is part of the Innovative Health Initiative Joint Undertaking's (IHI JU) annual call (Call 11) under the broader Horizon Europe program, indicating a recurring funding opportunity with a focus on public-private partnerships.

Funding

Up to 20202000.00 EUR

Deadline

April 29, 2026, midnight

Details

Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)

PAR-25-338

Programme: National Institutes of Health (NIH) Grants

This grant aims to stimulate the translation of scientific discoveries and engineering developments into practical methods and tools for understanding, assessing, detecting, preventing, diagnosing, treating, and managing diseases. It fosters collaboration by requiring academic-industrial partnerships.

Single, clear statement of grant's core objective: To translate biomedical scientific and engineering discoveries into new methods or tools for disease diagnosis and treatment through academic-industrial partnerships, explicitly excluding clinical trials.
Explicit identification of target recipient type and size: Research teams composed of at least one academic organization and one industrial organization, regardless of specific organizational size, but needing sufficient expertise and resources.
MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC (Healthcare, Biotechnology, Medical Research, Diagnostics, Medical Technology).
Geographic scope and any location requirements: Domestic (U.S.) and foreign organizations are eligible.
Key filtering criteria for initial grant screening:
- Must propose an academic-industrial partnership.
- Must focus on translation of technology/methods; clinical trials are not allowed.
- Must not be for commercial production or basic research lacking a translational aim.
Grant frequency and program context: Recurring funding opportunity, reissued from PAR-21-166, with multiple recurring submission deadlines up to October 2027.